Moomoo AI 已提取核心信息
On December 31, 2023, Altimmune, Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing, dated February 14, 2024, reports that Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, have updated their holdings in Altimmune's common stock. NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares. Collectively, these holdings represent a total of 3.21% of the company's common stock. The filing specifies that these shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers.
On December 31, 2023, Altimmune, Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing, dated February 14, 2024, reports that Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, have updated their holdings in Altimmune's common stock. NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares. Collectively, these holdings represent a total of 3.21% of the company's common stock. The filing specifies that these shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers.
2023年12月31日，生物制药公司Altimmune, Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，这表明重要投资者的所有权发生了变化。这份日期为2024年2月14日的文件报告称，总部位于特拉华州的Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL）已经更新了其在Altimmune普通股中的持有量。不结盟运动报告了6,679股股票的所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股股票。这些持股总共占公司普通股的3.21％。该文件指出，这些股份是在正常业务过程中收购的，无意改变或影响Altimmune的控制权。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该规则适用于某些机构投资经理。
2023年12月31日，生物制药公司Altimmune, Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，这表明重要投资者的所有权发生了变化。这份日期为2024年2月14日的文件报告称，总部位于特拉华州的Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL）已经更新了其在Altimmune普通股中的持有量。不结盟运动报告了6,679股股票的所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股股票。这些持股总共占公司普通股的3.21％。该文件指出，这些股份是在正常业务过程中收购的，无意改变或影响Altimmune的控制权。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该规则适用于某些机构投资经理。
有用
没用